Summary of Myanmar Clinical Practice Guidelines on the Management of Dyslipidaemia in Type 2 Diabetes Mellitus

Authors

  • Tint Swe Latt
  • Than Than Aye Department of Medicine, University of Medicine (2), Yangon, Myanmar
  • Ko Ko
  • Aung Cho Myint
  • Ye Myint

Abstract

Cardiovascular disease is a significant cause of morbidity and mortality in patients with diabetes mellitus (DM). According to the IDF Diabetes Atlas 2013, the prevalence of diabetes in Myanmar is 5.7%.(1) Diabetes is recognized as a risk equivalent for coronary heart disease. The lipid profile in patients with type 2 DM is characterized by elevated triglycerides, low high-density lipoprotein cholesterol and raised small dense low-density lipoprotein cholesterol (LDL-C) particles. This is believed to be a key factor in promoting atherosclerosis in these patients. There is ample evidence that aggressive statin therapy reduces cardiovascular end points in patients with DM in both primary and secondary prevention studies. In all persons with DM, current treatment guidelines recommend reduction of LDLC to less than 100 mg/dL, regardless of baseline lipid levels. In very high risk patients with DM and coronary heart disease lowering of LDL-C to less than 70 mg/dL may provide even greater benefits. Treatment for hypertriglyceridaemia is recommended only if TG levels is very high (>500 mg/dL).

Downloads

Download data is not yet available.

Author Biography

Than Than Aye, Department of Medicine, University of Medicine (2), Yangon, Myanmar

  •  Prof/Head of Medicine Department ,University of Medicine 2(Retired)
  •  Prof of Department of Endocrinology , University of Medicine 2  
  •  Vice President of Myanmar Society of Endocrinology & Metabolism (MSEM) 

References

International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas.

WHO step wise approach to NCDs surveillance Myanmar Standard Report (Level 1) 2003-2004.

American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014; 37 (Suppl. 1): S14-S80. http://dx.doi.org/10.2337/dc14-S014.

Haffner SM: Management of dyslipidaemia in adults with diabetes (Technical Review). Diabetes Care. 1998;21:160–178.

Barrett-Connor E. Diabetes and Heart disease. Diabetes Care.2003;2:2947-58.

http://dx.doi.org/10.2337/diacare.26.10.2947.

Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005; 366: 1267-

http://dx.doi.org/10.1016/S0140-6736(05)67394-1.

American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). Diabetes Care. 2003; 26 (Suppl. 1):S51–S61.

American Diabetes Association: Diabetes mellitus and exercise (Position Statement). Diabetes Care. 2001;24:S51–S55.

Expert Panel on Blood Cholesterol Levels in Children and Adolescents: Treatment recommendations of the National Cholesterol Education Program Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89 (Suppl.):525–

Downloads

Published

2014-11-29

How to Cite

Latt, T. S., Aye, T. T., Ko, K., Myint, A. C., & Myint, Y. (2014). Summary of Myanmar Clinical Practice Guidelines on the Management of Dyslipidaemia in Type 2 Diabetes Mellitus. Journal of the ASEAN Federation of Endocrine Societies, 29(2), 112. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/140

Issue

Vol. 29 No. 2 (2014): November Issue

Section

Feature Articles

License

Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).

To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.

A written agreement shall be emailed to the requester should permission be granted.

Most read articles by the same author(s)

1 2 > >>